Guggenheim raised the firm’s price target on Cidara Therapeutics (CDTX) to $70 from $69 and keeps a Buy rating on the shares. Following Cidara’s Q2 earnings release and call, the firm says it views the company as “exceptionally well positioned to execute” on its Phase 3 program and looks forward to potential FDA minutes and a BARDA decision as early as September.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $74 from $53 at H.C. Wainwright
- Cidara Therapeutics price target raised to $66 from $59 at Citizens JMP
- Cidara Therapeutics Reports Positive Trial Results and Financial Growth
- Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82)
- Cidara Therapeutics price target raised to $115 from $75 at RBC Capital